Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities betwee ...

In the latest close session, Adma Biologics (ADMA) was down 4.34% at $8.37. This change lagged the S&P 500's daily gain of 1.18%. At the same time, the Dow added 0.59%, and the tech-heavy Nasdaq ...

Adma Biologics (ADMA) closed the most recent trading day at $8.97, moving 1.21% from the previous trading session.

ADMA Biologics draws attention as plasma demand, vertical integration, legal risk, and defensive healthcare trends shape its ...

Learn more about whether ADMA Biologics, Inc. or CareDx, Inc. is a better investment based on AAII's A+ Investor grades, ...

Year-End 2025 Cash Grew to Approximately $88 Million with an Unaudited Operating Cash Flow Estimate of $40 Million in 4Q 2025 2026 Expected to be ADMA's First Full Year of Yield-Enhanced Production, ...

ADMA Biologics, Inc.’s ADMA shares have gained 13.5% in a month compared with the industry’s growth of 8.2%. The recovery ...

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ADMA and certain of its executives are charged with failing to disclose material information during the ...

ADMA Biologics (ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Zacks Consensus Estimate by a penny. Revenues of $122 million (up ...

These stocks are better bets to skyrocket than the much-hyped rocket stock.